Shattuck Labs, Inc. (STTK) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 4, 2025, details a material agreement entered into by Shattuck Labs, Inc., a Delaware corporation. The filing reports the execution of a Securities Purchase Agreement for a private placement of equity securities. The company is an emerging growth company focused on clinical development, specifically referencing its Phase 1 clinical trial for the asset SL-325.
Key Financial Metrics and Transaction Details
The filing outlines a capital raise transaction with the following specific terms:
- Securities Issued: 15,225,158 shares of Common Stock and Pre-Funded Warrants to purchase up to 37,410,188 shares.
- Warrants: Common Warrants to purchase up to 52,635,346 shares of Common Stock.
- Pricing: Combined price of $0.8677 per Share and Common Warrant; $0.8676 per Pre-Funded Warrant and Common Warrant.
- Expected Proceeds: Approximately $46 million in upfront gross proceeds (before fees and expenses).
- Potential Additional Proceeds: Approximately $57 million if all Common Warrants are exercised in full.
- Placement Agent: Wedbush & Co., LLC.
The filing does not provide current revenue, profit, cash flow, or debt metrics as this is a transactional report rather than a periodic financial statement.
Material Changes and Conditions
The transaction is subject to specific closing conditions, primarily the clearance of the Investigational New Drug (IND) Application for SL-325 by the U.S. Food and Drug Administration (FDA). Upon closing, certain purchasers will receive the right to designate directors to the Company's Board of Directors. The company will also enter into a Registration Rights Agreement, requiring the filing of a registration statement for the resale of securities within 30 calendar days of closing.
Outlook, Risks, and Management Commentary
Warrant Expiration: Common Warrants will expire on the 30th day following the public announcement of data from the single ascending dose and multiple ascending dose portions of the Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of planned Phase 2 clinical trials.
Beneficial Ownership Limitations: Holders are restricted from exercising warrants if it would result in beneficial ownership exceeding 4.99% (or 9.99% upon election), though this limit can be increased to 19.99% with 61 days' notice.
Risks: The closing is contingent on FDA clearance. The securities are unregistered and sold under Section 4(a)(2) of the Securities Act and Regulation D exemptions.
Key Facts for Investor Verification
- Verify the status of the IND Application for SL-325 with the FDA to confirm the closing condition.
- Confirm the final closing date and actual gross proceeds received after deducting placement agent fees and offering expenses.
- Monitor the upcoming Phase 1 clinical trial data announcement for SL-325, which triggers the expiration of Common Warrants.
- Review the composition of the Board of Directors post-closing to identify new designees from the purchasers.
- Check the filing of the registration statement for resale of securities within the mandated 30-day window post-closing.